Key Metrics 
Check Before You Invest 
10 Yrs X-Ray 
Valuation 
Analyst Note 
Qtr. Results 
Financials 
News 
About
Akums Drugs & Pharmaceuticals Ltd (AKUMS)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 544222 NSE: AKUMS Pharmaceuticals & Drugs | Small Cap | Akums Drugs & Pharma Share Price
₹776.45 26.35 (3.51%)
As on 11-Sep'26 15:13
Akums Drugs & Pharmaceuticals Ltd (AKUMS)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 544222 NSE: AKUMS Pharmaceuticals & Drugs | Small Cap | Akums Drugs & Pharma Share Price
₹776.45 26.35 (3.51%)
As on 11-Sep'26 15:13
Key Metrics
Valuation Multiples
Market Cap
₹11,806 Cr.
Current Price
₹776.5
52-Week Low / High
₹410 / 796
TTM EPS
₹18.5
TTM Sales
₹4,502 Cr.
Book Value per Share
₹217
P/E Ratio
40.47
Lower than its 5-year historical median
Industry PE
54.3
Price to Book (P/B)
3.46
Higher than its 5-year historical median
Price to Sales (P/S)
2.62
Lower than its 5-year historical median
EV/EBITDA
14.57
Lower than its 5-year historical median
Dividend Yield
0.39%
Profitability Efficiency
Return on Equity (ROE)
8.06%
Underperforms industry median
Return on Capital Employed (ROCE)
14.77%
Outperforms industry median
Return on Assets (ROA)
5.59%
Operating Profit Margin
12%
Net Profit Margin
5.88%
Gross Profit Margin
12.8%
Growth Momentum
1-yr vs 3-yr growth
1-yr vs 3-yr growth
Sales Growth (1 Year)
Improving versus 3-year growth rate
2.82%
Operating Profit Growth (1 Year)
Slowing versus 3-year growth rate
13.33%
Net Profit Growth (1 Year)
Slowing versus 3-year growth rate
-25.42%
Asset Quality
Promoter Holding
75.26%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
₹3,384 Cr.
Equity
₹31.5 Cr.
Face Value
₹2
All Time Low / High
₹407.40 / 1174.85
Check Before You Invest
Quality
Very GoodValuation
Somewhat OvervaluedCheck Valuation charts
Price Trend
Strong
Is Akums Drugs & Pharmaceuticals Ltd a good quality company?
Akums Drugs & Pharmaceuticals Ltd is a average quality company, based on a somewhat consistent multi-year financial track record.
This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.
We have analysed the performance of the company on the following:
-
How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
-
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
-
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.
How does Akums Drugs & Pharmaceuticals Ltd performance compare with that of its Peers?
Revenue growth of Akums Drugs & Pharmaceuticals Ltd vs industry peers?
Akums Drugs & Pharmaceuticals Ltd revenue CAGR is 10.00%, compared to the industry median CAGR of 5.76%, indicating faster growth and gaining its market share.
Promoter shareholding and pledge status of Akums Drugs & Pharmaceuticals Ltd?
Promoters hold 75.26% of the Akums Drugs & Pharmaceuticals Ltd, with 0.00% of their stake pledged, indicating no pledge risk.
Stock return of Akums Drugs & Pharmaceuticals Ltd over the last decade?
Over the last 1 year(s), the stock has delivered a CAGR of 60.39% based on the current price.
10 Year X-Ray :
Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year endData adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
What is a Financial Track Record? How to read this chart in order to understand the data present here?
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Akums Drugs & Pharmaceuticals Ltd has performed well in majority of the past ten years indicating its past ten year financial track record is very good
Value Creation ⓘ
| Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | 6.6% | 13.8% | 13.7% | 9.8% | -29.1% | -73.8% | 42.8% | -20.5% | 16.7% | 6.7% | - |
| Value Creation Index ⓘ | -0.5 | 0.0 | 0.0 | -0.3 | -3.2 | -6.5 | 2.2 | -2.5 | 0.2 | -0.5 | - |
Growth Parameters ⓘ |
|||||||||||
| Sales ⓘ | 628 | 596 | 683 | 737 | 837 | 1,162 | 1,287 | 1,444 | 1,312 | 1,349 | 1,409 |
| Sales YoY Gr. | - | -5.2% | 14.7% | 7.9% | 13.6% | 38.8% | 10.7% | 12.2% | -9.2% | 2.8% | - |
| Adj EPS ⓘ | 2.5 | 5.2 | 5.7 | 3.6 | 4.4 | -2.9 | 15.4 | 6.9 | 10.5 | 7.6 | 7.1 |
| YoY Gr. | - | 111.3% | 9% | -37.8% | 23.9% | -166.8% | NA | -55.3% | 53.3% | -27.7% | - |
| BVPS (₹) ⓘ | 54.1 | 59.4 | 65.1 | 49.8 | 39.6 | 13 | 21.8 | 10.1 | 150.6 | 158.6 | 157.1 |
| Adj Net Profit ⓘ | 32.1 | 67.7 | 73.9 | 50.8 | 63 | -42.1 | 220 | 98.3 | 161 | 117 | 112 |
| Cash Flow from Ops. ⓘ | 44.1 | 71.4 | 2.8 | -21.8 | 55.6 | 228 | 94 | 248 | 91 | -2.2 | - |
| Debt/CF from Ops. ⓘ | 1.3 | 0.5 | 18.2 | -1.7 | 0.4 | 0.5 | 1.6 | 0.9 | 0 | -6.3 | - |
CAGR ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | 8.9% | 10% | 1.6% | 2.8% | ||||
| Adj EPS ⓘ | 13.3% | 11.6% | -20.9% | -27.7% | ||||
| BVPSⓘ | 12.7% | 32% | 93.8% | 5.3% | ||||
| Share Price | - | - | - | 68.9% | ||||
Key Financial Parameters ⓘ
| Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | 4.7 | 9.2 | 9.2 | 6.5 | 9.8 | -11.2 | 88.5 | 43.2 | 13.2 | 4.9 | 4.5 |
| Op. Profit Mgn % ⓘ | 4.7 | 12.6 | 12 | 5.4 | 9.6 | 11.4 | 15.4 | 16 | 10.3 | 7.3 | 7.2 |
| Net Profit Mgn % ⓘ | 5.1 | 11.4 | 10.8 | 6.9 | 7.5 | -3.6 | 17.1 | 6.8 | 12.3 | 8.6 | 7.9 |
| Debt to Equity ⓘ | 0.1 | 0 | 0.1 | 0.1 | 0 | 0.7 | 0.5 | 1.6 | 0 | 0 | - |
| Working Cap Days ⓘ | 346 | 406 | 407 | 458 | 417 | 355 | 404 | 381 | 432 | 372 | 186 |
| Cash Conv. Cycle ⓘ | 102 | 92 | 88 | 93 | 84 | 64 | 61 | 55 | 52 | 53 | 146 |
Valuation of Akums Drugs & Pharma - Consolidated
Analyst's Notes
No data found!
Management X-Ray
Shareholding Pattern
Promoter's Holding & Share Pledging
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
* Pledged shares as % of Promoter's holding (%)
Financials
| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,857 | 1,552 | 2,008 | 2,414 | 2,723 | 3,672 | 3,655 | 4,178 | 4,118 | 4,359 |
| Operating Expenses ⓘ + | 1,663 | 1,353 | 1,826 | 2,240 | 2,431 | 3,764 | 3,361 | 4,055 | 3,658 | 3,837 |
| Operating Profit ⓘ | 195 | 199 | 182 | 174 | 291 | -92 | 294 | 123 | 461 | 522 |
| Operating Profit Margin (%) | 10.5% | 12.8% | 9.1% | 7.2% | 10.7% | -2.5% | 8.0% | 2.9% | 11.2% | 12.0% |
| Other Income ⓘ + | 9 | 15 | 22 | 27 | 21 | 23 | 90 | 34 | 56 | 129 |
| Interest ⓘ | 16 | 13 | 23 | 20 | 7 | 17 | 46 | 51 | 35 | 94 |
| Depreciation ⓘ | 46 | 52 | 56 | 67 | 70 | 95 | 113 | 126 | 153 | 155 |
| Profit Before Tax ⓘ | 143 | 150 | 126 | 114 | 172 | -193 | 150 | -45 | 345 | 382 |
| Tax ⓘ | 47 | 59 | 58 | 70 | 49 | 58 | 52 | -46 | 1 | 126 |
| Profit After Tax | 96 | 90 | 68 | 44 | 123 | -251 | 98 | 1 | 344 | 256 |
| PAT Margin (%) | 5.1% | 5.8% | 3.4% | 1.8% | 4.5% | -6.8% | 2.7% | 0.0% | 8.4% | 5.9% |
| Adjusted EPS (₹) | 7.4 | 7.0 | 5.3 | 3.3 | 8.6 | -17.7 | 6.6 | -0.3 | 22.1 | 16.7 |
| Dividend Payout Ratio (%) | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 18% |
| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | |||||||||||
| Shareholders Fund + | 711 | 795 | 856 | 722 | 885 | 622 | 717 | 709 | 3,047 | 3,313 | |
| Debt + | 183 | 159 | 227 | 140 | 87 | 351 | 503 | 446 | 14 | 73 | |
| Minority Interest | 21 | 29 | 35 | -2 | 2 | 3 | 6 | 11 | 17 | 18 | |
| Trade Payables | 147 | 244 | 210 | 423 | 341 | 590 | 567 | 532 | 643 | 602 | |
| Others Liabilities ⓘ | 137 | 162 | 207 | 753 | 836 | 1,484 | 1,441 | 1,695 | 185 | 1,270 | |
| Total Liabilities ⓘ | 1,200 | 1,389 | 1,535 | 2,037 | 2,152 | 3,050 | 3,235 | 3,393 | 3,905 | 5,276 | |
Fixed Assets | |||||||||||
| Net Fixed Assets ⓘ + | 603 | 649 | 652 | 644 | 904 | 1,021 | 1,097 | 1,191 | 1,397 | 1,456 | |
| CWIP ⓘ | 0 | 1 | 0 | 57 | 17 | 31 | 103 | 195 | 163 | 177 | |
| Investments ⓘ | 0 | 12 | 9 | 6 | 20 | 0 | 0 | 0 | 0 | 0 | |
| Inventories | 244 | 295 | 268 | 398 | 430 | 722 | 730 | 630 | 681 | 756 | |
| Trade Receivables | 295 | 334 | 473 | 582 | 531 | 884 | 845 | 834 | 770 | 797 | |
| Cash Equivalents | 7 | 18 | 21 | 147 | 68 | 103 | 150 | 277 | 576 | 1,681 | |
| Others Assets ⓘ | 51 | 80 | 112 | 202 | 183 | 289 | 310 | 266 | 317 | 410 | |
| Total Assets ⓘ | 1,200 | 1,389 | 1,535 | 2,037 | 2,152 | 3,050 | 3,235 | 3,393 | 3,905 | 5,276 | |
| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ + | 156 | 157 | -23 | 28 | 134 | 32 | 177 | 498 | 465 | 1,181 |
| Cash Flow From Investing Activity ⓘ + | -128 | -111 | -49 | -190 | -109 | -235 | -305 | -330 | -548 | -930 |
| Cash Flow From Financing Activity ⓘ + | -34 | -35 | 75 | 233 | -95 | 236 | 125 | -108 | 73 | 34 |
| Net Cash Flow ⓘ | -7 | 11 | 3 | 71 | -70 | 33 | -4 | 60 | -10 | 285 |
| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | 14.25 | 12.02 | 8.24 | 5.53 | 15.36 | -33.3 | 14.61 | 0.11 | 18.3 | 8.06 |
| ROCE (%) | 18.08 | 17.35 | 14.2 | 13.23 | 19.05 | -18 | 17.59 | 0.43 | 17.83 | 14.77 |
| Asset Turnover Ratio | 1.58 | 1.2 | 1.37 | 1.35 | 1.3 | 1.41 | 1.16 | 1.26 | 1.13 | 0.95 |
| PAT to CFO Conversion(x) | 1.63 | 1.74 | -0.34 | 0.64 | 1.09 | N/A | 1.81 | 498 | 1.35 | 4.61 |
| Working Capital Days | ||||||||||
| Receivable Days | 54.20 | 73.80 | 73.30 | 79.70 | 74.60 | 70.40 | 86.40 | 73.30 | 71.10 | 65.60 |
| Inventory Days | 52.20 | 63.40 | 51.20 | 50.40 | 55.50 | 57.30 | 72.50 | 59.40 | 58.10 | 60.20 |
| Payable Days | 51.90 | 77.40 | 62.80 | 78.40 | 82.50 | 72.50 | 92.80 | 78.70 | 88.10 | 90.40 |
Top 5 Mutual Funds Holding
Last Visited Stocks
Announcements
Akums Drugs & Pharmaceuticals Ltd FAQs
The current trading price of Akums Drugs & Pharma on 11-Sep-2026 15:13 is ₹776.5.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 10-Sep-2026 the market cap of Akums Drugs & Pharma stood at ₹11,806.1 Cr
The latest P/E ratio of Akums Drugs & Pharma as of 10-Sep-2026 is 105.8.
The latest P/B ratio of Akums Drugs & Pharma as of 10-Sep-2026 is 4.77.
The 52-week high of Akums Drugs & Pharma is ₹796.2 and the 52-week low is ₹410.1.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Akums Drugs & Pharma is ₹1,409 ( Cr.) .
Past 10 year's financial track record analysis by Moneyworks4me indicates that Akums Drugs & Pharmaceuticals Ltd is a good quality company.
The key valuation ratios of Akums Drugs & Pharmaceuticals Ltd's currently when compared to its past seem to suggest it is in the Somewhat overvalued zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Strong which suggest that the price of Akums Drugs & Pharmaceuticals Ltd is likely to Rise in the short term. However, please check the rating on Quality and Valuation before investing
About Akums Drugs & Pharmaceuticals Ltd
The company was incorporated as a public company, limited by shares, under the Companies Act, 1956, as amended, in the name of ‘Akums Drugs and Pharmaceuticals Limited’, pursuant to a certificate of incorporation dated April 19, 2004 issued by the Registrar of Companies, Delhi and Haryana in New Delhi (RoC). The company received a certificate of commencement of business issued by the RoC dated May 13, 2004.
Established in 2004, Akums Drugs and Pharmaceuticals is a pharmaceutical contract development and manufacturing organization (CDMO) offering a comprehensive range of pharmaceutical products and services in India and overseas. As one of the leading CDMOs in India, the company owns the intellectual property for the manufacturing processes of several of its formulations, and its core business is focused on providing end-to-end product development and manufacturing solutions to its clients. Some of its other services include formulation research and development (R&D), preparation and filing of regulatory dossiers in the Indian and global markets, and other testing services. In addition to its core CDMO business, it is also engaged in the manufacturing and sale of branded pharmaceutical formulations and active pharmaceutical ingredients (APIs).
Business area of the company
As a CDMO, the company produces an extensive range of dosage forms including tablets, capsules, liquid orals, vials, ampoules, blow-filled seals, topical preparations, eye drops, dry powder injections, and gummies, among others. It also engages in the marketing of trade generic and products under its own brand through distributors and alternative channels across India.
Key Awards and accreditations
- 2018: Received India Pharma Leader Award by Government of India.
- 2019: Received India Pharma Leader Award by Government of India.
- 2021: Award for India Pharma Award for Excellence in Contract Research and Manufacturing by Informamarkets.
- 2022: Award for Excellence in R&D and Innovation by ET Ascent.
- 2022: Awarded the International Healthcare award as Pharmaceutical Company of the Year in contract manufacturing by Times Cyber Media.
- 2022: Awarded the Excellence in Operations – Manufacturing by CPHI Awards.
- 2022: Awarded Asia’s Pharma Excellence Awards in Innovation in Nutraceutical, Cosmetic and Wellness Award by CMO Asia.
- 2023: Awarded Dream Employer of the Year by Times Ascent.
- 2023: Awarded the Excellence Award in Nutraceutical category by IHW Council.
- 2023: Award for the best brand based in North India by Exchange4Media.
- 2023: Awarded the best Technology Adaption – Cash Management Services by HDFC Bank.
- 2023: Awarded 2nd Runner up in Best Trademarks portfolio by CII Industrial Intellectual Property Awards.
- 2023: Awarded the Excellence in Formulations by India Pharma World Awards, The Economic Times.
- 2023: Awarded the Most Admired Quality Pharmaceutical Manufacturer of India 2023 by Observe Now.
- 2023: Awarded the Certificate of Appreciation for Excellence in Innovative Formulations – Nutraceutical and Wellness Award by Food Safety and Nutrition Summit and Awards 2023.
Major events and milestones
- 2004: Incorporation of the company.
- 2004: Established first plant for oral dosage commissioned at 19, 20, 21, sector 6A, Haridwar, Uttarakhand.
- 2007: Established dedicated manufacturing site for oral liquid dosage at 22, Sector 6A, Sidcul, Haridwar, Uttarakhand and sterile products at 2,3,4,5, Sector 6B, SIDCUL, Haridwar, Uttarakhand.
- 2009: Incorporated Maxcure Nutravedics Limited to venture into nutraceuticals.
- 2010: Dedicated a facility for hormones at 48, Sector 6A, SIDCUL, Haridwar, Uttarakhand.
- 2010: Dedicated a facility for cosmetics and dermatology at 47, Sector 6A, SIDCUL, Haridwar, Uttarakhand.
- 2010: Incorporated Akumentis Healthcare Limited to venture into branded formulations.
- 2011: Innovated bi-layered sustained release tablets for the first time.
- 2012: Acquired Pure and Cure Healthcare Private Limited to expand capacity and capabilities.
- 2013: Innovated tablet-in-tablet sustained release tablets for the first time.
- 2013: Acquired Malik Lifesciences Private Limited manufacturing sites to expand capacity and capabilities.
- 2013: Expanded into the African market.
- 2015: Expanded into the Asian market.
- 2015: Established research and development laboratory in Mumbai, Maharashtra to venture into regulated market.
- 2016: Maxcure Nutravedics Limited received US-NSF certification.
- 2019: Investment by Ruby QC Investment Holdings Pte. Ltd. in the company to become a minority shareholder.
- 2021: Acquired Parabolic Drugs to form Akums Lifesciences Limited and ventured into APIs.
- 2021: Acquisition of a facility at Kotdwar, Uttarakhand by Akums Healthcare Limited.
- 2022: Plant at 19, 20, 21, Sector 6A, SIDCUL, Haridwar, Uttarakhand and plant at 2, 3, 4,5, Sector 6B, SIDCUL, Haridwar, Uttarakhand accredited European Union-Good Manufacturing Practices, qualifying for exports to European markets.
- 2022: Acquisition of a facility in Haridwar, Uttarakhand by Akums Healthcare Limited and a facility in Baddi, Himachal Pradesh by Pure and Cure Healthcare Private Limited.
- 2023: Acquisition of another facility in Baddi, Himachal Pradesh by Pure and Cure Healthcare Private Limited.
- 2023: Merger of Akums Lifesciences Limited with Pure and Cure Healthcare Private Limited.
You have 34 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
